707 related articles for article (PubMed ID: 31614690)
1. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.
Cheng HS; Tan WR; Low ZS; Marvalim C; Lee JYH; Tan NS
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614690
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
3. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
4. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
5. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
7. The Role of PPARs in Disease.
Wagner N; Wagner KD
Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
[TBL] [Abstract][Full Text] [Related]
8. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
9. Biology and therapeutic applications of peroxisome proliferator- activated receptors.
Menendez-Gutierrez MP; Roszer T; Ricote M
Curr Top Med Chem; 2012; 12(6):548-84. PubMed ID: 22242855
[TBL] [Abstract][Full Text] [Related]
10. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
11. The role of peroxisome proliferator-activated receptors in healthy and diseased eyes.
Escandon P; Vasini B; Whelchel AE; Nicholas SE; Matlock HG; Ma JX; Karamichos D
Exp Eye Res; 2021 Jul; 208():108617. PubMed ID: 34010603
[TBL] [Abstract][Full Text] [Related]
12. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
13. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
Hong F; Xu P; Zhai Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
[TBL] [Abstract][Full Text] [Related]
14. The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.
Dixit G; Prabhu A
Exp Mol Pathol; 2022 Feb; 124():104723. PubMed ID: 34822814
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics?
Gupta M; Mahajan VK; Mehta KS; Chauhan PS; Rawat R
Arch Dermatol Res; 2015 Nov; 307(9):767-80. PubMed ID: 25986745
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses.
Aleshin S; Strokin M; Sergeeva M; Reiser G
Neurochem Int; 2013 Oct; 63(4):322-30. PubMed ID: 23811400
[TBL] [Abstract][Full Text] [Related]
17. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
Mirza AZ; Althagafi II; Shamshad H
Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
19. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
20. The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.
Cheang WS; Tian XY; Wong WT; Huang Y
Br J Pharmacol; 2015 Dec; 172(23):5512-22. PubMed ID: 25438608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]